To view this website, turn your mobile
device to its upright/vertical position.


Unique mechanism of action1,2

MYOBLOC blocks the release of acetylcholine (ACh) to inhibit muscle contraction.1,2
  • MYOBLOC has been demonstrated to cleave synaptic vesicle-associated membrane protein (VAMP)2*
  • This blocking action allows the injected muscle to assume a more normal tone
Inhibition of ACh at the neuromuscular junction occurs through the 4-stage process.1,2

Neurospecific binding of the toxin on the presynaptic nerve surface

of the toxin by receptor-mediated endocytosis

Subsequent translocation of the toxin light chain into the cystol

Modification of an intracellular target substrate that governs the docking and fusion of ACh‑containing vesicle

*VAMP is a component of the protein complex responsible for docking and fusion of the synaptic vesicle to the presynaptic membrane, a necessary step to neurotransmitter release.


Relieves symptom severity and neck pain from cervical dystonia (CD) in adults1–4

  • EFFECTIVE first-line treatment
  • PAIN RELIEF as early as 2 weeks5,6
  • DURATION OF ACTION 12–16 weeks1,2
  • READY TO USE and requires no mixing
  • SIGNIFICANT improvement in head posture by week 41,2
EFFECTIVE first-line treatment
PAIN RELIEF as early as 2 weeks5,6
DURATION OF ACTION 12–16 weeks1,2
READY TO USE and requires no mixing
SIGNIFICANT improvement in head posture by week 41,2



Clinical Data: MYOBLOC relieves symptom severity and neck pain from cervical dystonia (CD)1–4

Results support that MYOBLOC can be an effective first-line treatment for patients with CD who list pain as a predominant complaint8


  • The mean improvement of the MYOBLOC treated groups was statistically significant versus placebo, demonstrating the efficacy of MYOBLOC in patients with CD1-3
  • MYOBLOC produced clinically and statistically significant pain relief on a patient-reported Visual Analog Scale (VAS)1
  • Treatment with MYOBLOC significantly reduced neck pain in a second placebo-controlled trial2

* P < 0.05 vs placebo
TWSTRS-Total and TWSTRS-Pain scores in Study #402 were numerically greater with MYOBLOC than Botox, but these differences were not statistically significant7

Study #9 - A randomized, double-blind, placebo-controlled safety and efficacy study of MYOBLOC. A total of 122 patients were enrolled and randomized between doses of placebo, 2,500 Units, 5,000 Units, and 10,000 Units.

Study #301 - A randomized, double-blind, multicenter, placebo-controlled, 16-week trial to determine the safety and efficacy of MYOBLOC in patients with cervical dystonia who were responsive to Botox. A total of 109 patients were randomized to receive injections of MYOBLOC 5,000 Units, MYOBLOC 10,000 Units, or placebo.

Study #302 - A randomized, double-blind, multicenter, placebo-controlled, 16-week trial to determine the safety and efficacy of MYOBLOC in patients with cervical dystonia who were resistant to Botox. A total of 77 patients were randomized to receive injections of MYOBLOC 10,000 Units or placebo. The most frequent, clinically relevant adverse events were dry mouth and dysphagia.

Study #402 - A randomized, double-blind, multicenter, noninferiority trial comparing the efficacy, safety, and duration of effect of Botox with MYOBLOC in patients with cervical dystonia. Subjects, who were new to treatment with botulinum toxins, were randomized to receive injections of Botox 150 Units or MYOBLOC 10,000 Units.

Botox® marks owned by Allergan, Inc.


Clinical Data: MYOBLOC provides consistent pain relief with repeated administration7

The mean TWSTRS-Pain scores at week 4 appear to be maintained across treatment sessions compared with baseline scores7

Four-hundred twenty-seven subjects with a mean age of 55.1 years enrolled in the study, which represented the largest prospective report of long-term open-label MYOBLOC treatment in CD9

On the first injection, subjects were administered 5,000 Units (toxin-naïve subjects who previously received placebo), 10,000 Units, or the highest MYOBLOC dose previously received. Re-injection occurred when the patient returned to approximate CD baseline status at least 3 months out from the last injection9

TWSTRS scales were performed at baseline and 4 weeks post-treatment9


TWSTRS: A validated scale for assessing cervical dystonia10–12

TWSTRS is an assessment scale used to measure the impact of cervical dystonia on patients.13 It is frequently used in clinical trials for cervical dystonia, including trials for MYOBLOC.

It is comprised of 3 subscales: Severity, Disability, and Pain, each of which is scored independently. The total of these 3 comprises the TWSTRS total score which is scored from 0–87 (best to worst).

1. Severity (0 to 35)
  • Maximal excursion
    • Rotation
    • Laterocollis
    • Anterocollis/retrocollis
    • Lateral shift
    • Sagittal shift
  • Duration factor (weighted x 2)
  • Effect of sensory tricks
  • Shoulder elevation/anterior displacement
  • Range of motion
  • Time
2. Disability (0 to 32)

Effect of cervical dystonia on ability to perform activities, including:

  • Work
  • Activities of daily living
  • Driving
  • Reading
  • Television
  • Activities outside the home
3. Pain (0 to 20)
  • Severity of pain
  • Duration of pain
  • Disability due to pain

Abbreviation: TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale.

Visual Analog Scale (VAS)14

The VAS is a subjective scale for assessing a variable such as patient-reported pain. It is a 100-mm line, usually horizontal, anchored on both ends with descriptors (see figure). A patient marks the point that he/she feels represents the variable being measured (e.g., pain). The score, from 0 to 100, is determined by measuring from the end of the line to the patient’s mark.


  1. 1. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999;53:1439–1446.
  2. 2. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;53:1431–1438.
  3. 3. Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology. 1997;49:701–707.
  4. 4. MYOBLOC® US Prescribing Information. Solstice Neurosciences, LLC; Louisville, KY: 2010.
  5. 5. Data on file, MYO-021-0907. Solstice Neurosciences, LLC; Louisville, KY: 2007.
  6. 6. Data on file, MYO-022-0907. Solstice Neurosciences, LLC; Louisville, KY: 2007.
  7. 7. Pappert EJ, Germanson T. NeuroBloc botulinum toxin type B vs type A in toxin-naïve patients with cervical dystonia: randomized, double-blind, non-inferiority trial. Mov Disord. 2008;23(4): 510–517.
  8. 8. Lew MF, Chinnapongse R, et al. RimabotulinumtoxinB effects on pain associated with cervical dystonia: results of placebo and comparator-controlled studies. Int J Neurosci. 2010;120:298–300.
  9. 9. Lew MF, Factor SA. Botulinum toxin type B (Myobloc) is well tolerated and efficacious in a long-term observational study: results of an open-label extension trial of repeated dosing in subjects with cervical dystonia. Neurology. 2006;66(suppl 2):A290–A291.
  10. 10. Consky ES, Lang AE. Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallett M, eds. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker, Inc; 1994:211-237.
  11. 11. Comella CL, Jankovic J, Shannon KM, et al; Dystonia Study Group. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005;65:1423-1429.
  12. 12. Factor SA, Molho ES, Evans S, Feustel PJ. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia. Mov Disord. 2005;20(9):1152-1160.
  13. 13. Consky ES, Basinki A, Belle L, et al. The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): assessment of validity and inter-rater reliability. Neurology. 1990;40(suppl 1):445.
  14. 14. Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health. 1990;13(4):227-236.


MYOBLOC® (rimabotulinumtoxinB) injection is indicated for:

  • the treatment of cervical dystonia (CD) to reduce the severity of abnormal head position and neck pain associated with CD in adults
  • the treatment of chronic sialorrhea in adults



See full prescribing information for complete boxed WARNING.

The effects of MYOBLOC® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults, particularly in those patients who have an underlying condition that would predispose them to these symptoms.


MYOBLOC is contraindicated in patients with:

  • A known hypersensitivity to any botulinum toxin product or to any of the components in the formulation
  • Infection at the proposed injection site(s)


Lack of Interchangeability Between Botulinum Toxin Products
The potency units of MYOBLOC are specific to the preparation and biological activity assay method utilized. Due to differences in the aspects of this assay such as the vehicle, dilution scheme, and laboratory protocols for various potency assays, potency units are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of MYOBLOC cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method.

Hypersensitivity Reactions
Serious hypersensitivity reactions have been reported with botulinum toxin products. Angioedema, urticaria, and rash have occurred with MYOBLOC treatment. Hypersensitivity reactions can also include anaphylaxis, serum sickness, soft tissue edema, and dyspnea. If serious and/or immediate hypersensitivity reactions occur, discontinue further injection of MYOBLOC and institute appropriate medical therapy immediately. The use of MYOBLOC in patients with a known hypersensitivity to any botulinum neurotoxin or to any of the excipients (human albumin, sucrose), could lead to a life-threatening allergic reaction.

Dysphagia and Breathing Difficulties
Treatment with MYOBLOC and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or swallowing. When distant effects occur, additional respiratory muscles may be involved. Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin. Dysphagia may persist for several months and require use of a feeding tube to maintain adequate nutrition and hydration. Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised.

Cervical Dystonia:
Treatment of cervical dystonia with botulinum toxins may weaken neck muscles that serve as accessory muscles of ventilation. This may result in a critical loss of breathing capacity in patients with respiratory disorders who may have become dependent upon these accessory muscles. There have been postmarketing reports of serious breathing difficulties, including respiratory failure, in cervical dystonia patients. Patients treated with botulinum toxin may require immediate medical attention should they develop problems with swallowing, speech or respiratory disorders. These reactions can occur within hours to weeks after injection with botulinum toxin.

Pre-Existing Neuromuscular Disorders
Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of MYOBLOC.

Human Albumin and Transmission of Viral Diseases
This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would be considered extremely remote. No cases of transmission of viral diseases, CJD, or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.

MOST COMMON ADVERSE REACTIONS (>5% of patients and >5% more than placebo)

Cervical Dystonia: dry mouth, dysphagia, injection site pain, headache
Sialorrhea: dry mouth, dysphagia


Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated. Use of anticholinergic drugs after administration of MYOBLOC may potentiate systemic anticholinergic effects. The effect of administering different botulinum toxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin. Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of MYOBLOC.

To report SUSPECTED ADVERSE REACTIONS or product complaints, contact Supernus Pharmaceuticals, Inc. at 1-888-461-2255, Option 2. You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or

Please see the full Prescribing Information, including Boxed WARNING and Medication Guide.